Differences in CD33 intensity between various myeloid neoplasms

American Journal of Clinical Pathology

Volumn 118, Issue 4, 2002, Pages 560-566

  Jilani, Iman ^a   Estey, Elihu ^a   Huh, Yang ^a   Joe, Youngson ^a   Manshouri, Taghi ^a   Yared, Marwan ^a   Giles, Francis ^a   Kantarjian, Hagop ^a   Cortes, Jorge ^a   Thomas, Deborah ^a   Keating, Michael ^a   Freireich, Emil ^a   Albitar, Maher ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute myeloid leukemia; CD33 intensity; Chronic myelogenous leukemia; Gemtuzumab ozogamicin; Monoclonal antibody therapy; Myelodysplastic syndrome; Myeloproliferative disorder; Mylotarg; Quantitative flow cytometry

Indexed keywords

CD33 ANTIGEN; GEMTUZUMAB OZOGAMICIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; DIFFERENTIATION ANTIGEN; GEMTUZUMAB; IMMUNOTOXIN; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BONE MARROW; CELL DIFFERENTIATION; CELL SURFACE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; HUMAN; MAJOR CLINICAL STUDY; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; BONE MARROW CELL; FLOW CYTOMETRY; IMMUNOLOGY; IMMUNOPHENOTYPING; LEUKEMIA; MIDDLE AGED; MORTALITY; MYELODYSPLASTIC SYNDROME; PATHOLOGY; PROSPECTIVE STUDY; REPRODUCIBILITY; SINGLE BLIND PROCEDURE; SURVIVAL; SURVIVAL RATE; TREATMENT OUTCOME;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTINEOPLASTIC AGENTS; BONE MARROW CELLS; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; IMMUNOTOXINS; LEUKEMIA; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; SINGLE-BLIND METHOD; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 18244428964     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/1WMW-CMXX-4WN4-T55U     Document Type: Article

References (28)

1. Andrews R, Torok-Storb B, Bernstein I. Myeloid-associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies. Blood. 1983;62:124-132.
2. Giles F, Kantarjian H, Kornblau S, et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer. 2001;92:406-413.
3. Bross P, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7:1490-1495.
4. Larson RA. Current use and future development of gemtuzumab ozogamicin. Semin Hematol. 2001;38(3 suppl 6):24-31.
5. Sievers E, Larson R, Stadtmauer E, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19:3244-3254.
6. Sievers E. Targeted therapy of acute myeloid leukemia with monoclonal antibodies and immunoconjugates. Cancer Chemother Pharmacol. 2000;46(suppl):S18-S22.
7. Scheinberg DA, Lovett D, Divigi CR, et al. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J Clin Oncol. 1991;9:478-490.
8. Appelbaum FR, Matthews DC, Eary JF, et al. The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. Transplantation. 1992;54:829-833.
9. van der Jagt RH, Badger CC, Appelbaum FR, et al. Localization of radiolabeled antimyeloid antibodies in a human acute leukemic xenograft tumor model. Cancer Res. 1992;52:89-94.
10. Andrews R, Singer J, Bernstein I. Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties. J Exp Med. 1989;169:1721-1731.
11. Griffin JD, Linch D, Sabbath K, et al. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk Res. 1984;8:521-534.
12. Dinndorf PA, Andrews RG, Benjamin D, et al. Expression of normal myeloid-associated antigens by acute leukemia cells. Blood. 1986;67:1048-1053.
13. Bernstein ID, Singer JW, Smith FO, et al. Differences in the frequency of normal and clonal precursors of colony-forming cells in chronic myelogenous leukemia and acute myelogenous leukemia. Blood. 1992;79:1811-1816.
14. Schwartz A, Hetzel AD, Fernandez-Repollet E. QuickCal Plus: an automated system to determined the fluorescence intensity of labeled cells in MESF units [abstract]. Cytometry Suppl. 1991;5:136.
15. Zagursky RJ, Sharp D, Solomon KA, et al. Quantitation of cellular receptors by a new immunocytochemical flow cytometry technique. Biotechniques. 1995;18:504-509.
16. Schwartz A, Fernandez-Repollet E, Vogt R, et al. Construction of a uniform and standardized calibration curve for determination of fluorescence intensity by flow cytometry. Cytometry. 1996;26:22-31.
17. Schwartz A, Marti GE, Poon R, et al. Standardizing flow cytometry: a classification system of fluorescence standards used for flow cytometry. Cytometry. 1998;33:106-114.
18. Schwartz A, Ottinger J, Wallace E, et al. Quantitative determination of antibody binding capacity (ABC) by flow cytometry. Eur J Histochem. 1994;38(suppl 1):13-20.
19. Bernstein ID. Monoclonal antibodies to the myeloid stem cells: therapeutic implication of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate. Leukemia. 2000;14:474-475.
20. Terstappen LWMM, Hollander Z, Meiners H, et al. Quantitative comparison of myeloid antigens on five lineages of mature peripheral blood cells. J Leukoc Biol. 1990;48:138-148.
21. Knapp W. Flow cytometric analysis of cell-surface and intracellular antigens in leukemia diagnosis. Cytometry. 1994;8:187-198.
22. Zagursky RJ. Quantitation of cellular receptors by a new immunocytochemical flow cytometry technique. Biotechniques. 1995;3:504-509.
23. Huh Y, Keating M, Saffer H, et al. Higher levels of surface CD20 expression on circulating lymphocytes compared with bone marrow and lymph nodes in B-cell chronic lymphocytic leukemia. Am J Clin Pathol. 2001;116:437-443.
24. van der Velden VHJ, te Marvelde JG, Hoogeveen P, et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood. 2001;97:3197-3204.
25. White C, Weaver R, Grillo-Lopez A. Antibody-targeted immunotherapy for treatment of malignancy. Annu Rev Med. 2001;52:125-145.
26. Neumeister P, Ebil M, Zinke-Cerwenka M, et al. Hepatic veno-occlusive disease in two patients with relapsed acute myeloid leukemia treated with anti-CD33 calicheamicin (CMA-676) immunoconjugate. Ann Hematol. 2001;80:119-120.
27. De Vetten MP, Jansen JH, Van Der Reijden BA, et al. Molecular remission of Philadelphia/bcr-abl-positive acute myeloid leukemia after treatment with anti-CD33 calicheamicin conjugate (gemtuzumab ozogamicin, CMA0-676). Br J Haematol. 2000;111:277-279.
28. Thorson JS, Sievers EL, Ahlert J, et al. Understanding and exploiting nature's chemical arsenal: the past, present and future of calicheamicin research. Curr Pnarm Des. 2000;6:1841-1879.